University of California San Francisco
San Francisco General Hospital
Box 0809, Bldg NH 2A2
San Francisco, California 94143
phone: (415) 206-8505
fax: (415) 285-2037
email: phopewell@medsfgh.ucsf.edu
Dr Hopewell received his M.D. degree
from West Virginia University in 1965 and trained in internal
medicine and pulmonary disease at the University of California,
San Francisco. He joined the faculty at UCSF in 1973 and has remained
there since. His other experience includes two years in the U.S.
Public Health Service, one year with the Ministry of Health and
the World Health Organization in Peru and six months with the
Government of Nigeria, all working in tuberculosis control. Dr.
Hopewell succeeded John Murray as Chief of the Division of Pulmonary
and Critical Care Medicine at San Francisco General Hospital in
1989 and stepped down from that position to become Associate Dean
at SFGH in 1998. In addition to his administrative responsibilities,
Dr. Hopewell continues to be actively involved in the clinical
activities of the Division, attending both in the Medical ICU
and on the Pulmonary Consultation Service.
Dr. Hopewell's research activities relate to clinical and epidemiological
aspects of tuberculosis and tuberculosis control. He has worked
in close collaboration with the San Francisco Department of Public
Health Division of Tuberculosis Control in establishing an ongoing
research and training program, largely focussed on the scientific
basis of tuberculosis control. For the past nine years he has
been principal investigator in an NIAID-funded study of the molecular
epidemiology of tuberculosis. Over the course of these studies
a number of important observations have been made that have been
used to improve control efforts. Currently, working with collaborators
Peter Small, Joel Ernst, Chuck Daley and Dennis Osmond, the molecular
epidemiology project is expanding to examine human gene expression
in response to well-characterized exposures to M. tuberculosis.
Likewise, genetic variability among organisms having differing
degrees of infectivity as determined epidemiologically is being
examined. In addition Dr Hopewell is involved in studies of early
bactericidal activity of putative antituberculosis drugs as well
as clinical trials of various regimens.
In addition to research Dr Hopewell is the PI for a CDC-funded
national tuberculosis center, The Francis J. Curry National Tuberculosis
Center, also a collaboration between UCSF and the San Francisco
tuberculosis control program. The center provides training in
tuberculosis nationally and internationally and also develops
and evaluates innovations related to various aspects of tuberculosis
control.
Dr Hopewell is involved in a variety of international tuberculosis
control activities including the Stop Tb Initiative, the Tuberculosis
Consortium for Technical Assistance, the Global Investment Plan
for Tuberculosis, and WHO advisory groups.
Selected publications
Markowitz N, Hansen NI, Hopewell PC,
Glassroth J, Kvale PA, Mangura BT, Wilcosky TC, Wallace JM, Rosen
MJ, Reichman LB, and the Pulmonary Complications of HIV Infection
Study Group. Incidence of tuberculosis in the United States among
HIV-infected persons. Ann Intern Med 126:123-132, 1997.
Chambers, HF, Kocagöz T, Sipit T, Turner J, Hopewell PC.
Activity of amoxicillin/clavulanate in patients with tuberculosis.
Clinical Infectious Diseases 26:874-877, 1998.
Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small
PM. Predictive value of contact investigation for identifying
recent transmission of Mycobacterium tuberculosis. Am J Respir
Crit Care Med 158:465-469, 1998.
Hopewell PC. Using conventional and molecular epidemiological
analyses to target tuberculosis control interventions in a low
incidence area. Novartis Foundation Symposium, 217:42-54; discussion
54-56, 1998.
Chin DP, DeRiemer K, Small PM, Ponce de Leon A, Steinhart R, Schecter
GF, Daley CL, Moss AR, Paz EA, Jasmer RM, Agasino CB, Hopewell
PC. Differences in contributing factors to tuberculosis incidence
in the United States-born and foreign-born populations. Am J Respir
Crit Care Med 158:1797-1803, 1998.
Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after
travel to or contact with visitors with a high prevalence of tuberculosis.
Am J Respir Crit Care Med 158:1871-1875, 1998.
Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley
CL, Small PM. Transmission of Mycobacterium tuberculosis from
AFB smear-negative patients. Lancet 353:444-449, 1999.
Jasmer RM, Hahn JA, Small PM, Daley CL, Behr MA, Moss AR, Schecter
GF, Paz EA, Hopewell PC. A molecular epidemiologic analysis of
tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med
130:971-978, 1999.
Hopewell PC. Translating discoveries into control of tuberculosis
in HIV-infected persons. Internat J Tuberc Lung Dis 4:S82-S87,
2000.
Hopewell PC. Global tuberculosis control: an optimist’s perspective.
Internat J Tuberc Lung Dis 3:270-272, 1999.
Moss AR, Hahn JA, Tulsky JP, Daley CD, Small PM, Hopewell PC.
Tuberculosis in the homeless. A prospective study. Am J Respir
Crit Care Med 162:460-464, 2000.
Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff
E, King MD, Kawamura LM, Hopewell PC. Short-course rifampin and
pyrazinamide compared with isoniazid for latent Tuberculosis infection:
a multicenter clinical trial. Ann Intern Med. 2002;137:640-7.
Hopewell PC. Tuberculosis control: how the world has changed since
1990. Bull World Health Organ. 2002;80:427.
Rhee JT, Tanaka MM, Behr MA, Agasino CB, Paz EA, Hopewell PC,
Small PM. Use of multiple markers in population-based molecular
epidemiologic studies of tuberculosis. Int J Tuberc Lung Dis.
2000;4:1111-9.
Hopewell PC. Targeting tuberculosis prevention. Am J Respir Crit
Care Med. 2000;162:2017-8.
